Daito Pharmaceutical
4577.TPharmaceutical
Filed as Daito Pharmaceutical Co.,Ltd. (2022-08–2026-08)
Financials · Standalone
| Fiscal year ended | 2026-05 | 2025-05 | 2024-05 | 2023-05 | 2022-05 | 2021-05 |
|---|---|---|---|---|---|---|
| Revenue | ¥50.6bn | ¥50.4bn | ¥46.6bn | ¥44.7bn | ¥43.2bn | ¥48.5bn |
| Operating income | ¥3.6bn | ¥2.4bn | ¥3.8bn | ¥5.0bn | ¥6.0bn | ¥5.1bn |
| Ordinary income | ¥3.8bn | ¥2.5bn | ¥3.9bn | ¥5.1bn | ¥6.2bn | ¥5.3bn |
| Total assets | ¥72.5bn | ¥72.6bn | ¥72.8bn | ¥65.4bn | ¥59.7bn | ¥53.1bn |
| Net assets / equity | ¥52.3bn | ¥47.1bn | ¥47.8bn | ¥46.5bn | ¥43.4bn | ¥38.1bn |
| EPS (basic) | ¥265.65 | ¥49.74 | ¥103.54r | ¥110.37r | ¥144.1r | ¥122.74r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-06-01 → 2026-05-31 | Annual | 198 figures · EDINET |
22 more reports are still being processed.